Novo Nordisk stock slumped early Monday as the drugmaker was facing a hit to revenue from several different directions. This ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...

Tesla Shares in electric vehicle maker Tesla have climbed back to their highest point since February, amid investor optimism ...